IVZ
Invesco Ltd.
IVZ offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
JPM
JPMorgan Chase & Co.
JPM has a slight edge over IVZ overall, supported by stronger fundamentals and stronger modeled upside.
IVZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| N/A | |
| N/A |
IVZ's revenue is currently healthy, but its profitability is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IVZ.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
IVZ PE Valuation
IVZ has no meaningful PE right now: it lost money over the past year.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
IVZ Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for IVZ, with profitability improving.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
IVZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.15 | — |
| Q1 2025 | $1.25 | +$1.99 |
| Q4 2024 | $1.18 | +$1.91 |
| Q3 2024 | -$0.91 | -169% |
| Q2 2024 | -$0.74 | -152% |
| Q1 2024 | -$0.74 | -154% |
| Q4 2023 | -$0.73 | -149% |
| Q3 2023 | $1.31 | -34% |
| Q2 2023 | $1.41 | -39% |
JPM has the stronger earnings trend. Trailing diluted EPS is down 176% for IVZ versus JPM up 18%.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
IVZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +14% |
| Q2 2026 | $1.8B | +20% |
| Q1 2026 | $1.7B | +14% |
| Q4 2025 | $1.7B | +6.2% |
| Q3 2025 | $1.6B | +8.2% |
| Q2 2025 | $1.5B | +2.2% |
| Q1 2025 | $1.5B | +3.7% |
| Q4 2024 | $1.6B | +13% |
IVZ has the edge over JPM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +6.8 points |
| Q2 2026 | 20% | +5.8 points |
| Q1 2026 | 19% | +1 points |
| Q4 2025 | -86% | -106 points |
| Q3 2025 | 17% | +9.9 points |
| Q2 2025 | 14% | +0.2 points |
| Q1 2025 | 18% | +3.7 points |
| Q4 2024 | 20% | +96 points |
IVZ's operating margin was 23% last quarter, up 6.8 points from the same quarter a year ago.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM has the edge over IVZ on profitability, with a higher operating margin.
IVZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $442.8M | -24% |
| Q2 2026 | $703.7M | +33% |
| Q1 2026 | $198.4M | +$306.4M |
| Q4 2025 | $432.2M | +33% |
| Q3 2025 | $586.4M | +43% |
| Q2 2025 | $530.4M | +15% |
| Q1 2025 | -$108M | -$32.6M |
| Q4 2024 | $323.9M | -52% |
IVZ has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
IVZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.9M shares |
| 1 year | -0.5% | -2.1M shares |
| 3 years | -1.4% | -6.3M shares |
| 5 years | -2.9% | -13.7M shares |
| Available history | +2.7% | +12M shares |
IVZ has 453M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $75M |
| Q2 2026 | $50.4M |
| Q1 2026 | $69.2M |
| Q4 2025 | $25.8M |
| Q3 2025 | $29.2M |
| Q2 2025 | $25.5M |
| Q1 2025 | $43.1M |
| Q4 2024 | $26M |
IVZ spent $220M buying back its own shares over the past year, up 78% from the year before.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over IVZ on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
IVZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | -0.1x | Net Cash |
| Q3 2023 | 0.2x | Very low |
| Q2 2023 | 0.4x | Very low |
| Q1 2023 | 0.5x | Very low |
| Q4 2022 | 0.0x | Very low |
IVZ's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like IVZ.
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
IVZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 11.7 | Oversold |
IVZ's weekly RSI is 48 (neutral) and its Stochastic is 12 (oversold).
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
IVZ PE vs Financial Services Sector
| Metric | IVZ | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IVZ has no meaningful PE right now: it lost money over the past year.
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
IVZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.2% below |
| 20 week MA | $30.0 | 5.2% below |
| 50 week MA | $27.8 | 2.3% above |
| 100 week MA | $23.2 | 23% above |
| 200 week MA | $19.7 | 45% above |
IVZ has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 45% above its 200-week average.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over IVZ on trend strength, trading above more of its moving averages.
IVZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.8 | $17.6 | -1.2% |
| 2021 | $17.6 | $23.3 | +33% |
| 2022 | $23.3 | $18.4 | -21% |
| 2023 | $18.4 | $17.8 | -2.9% |
| 2024 | $17.8 | $17.7 | -0.9% |
| 2025 | $17.7 | $27.0 | +52% |
| 2026 YTD | $27.0 | $28.5 | +5.6% |
IVZ has the edge over JPM on returns for 2026, with the stronger performance.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has finished higher in four of the last six years. It's up 4.5% so far in 2026.